Clinical trial
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2…
NCT00387907 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00387907 |
|---|---|
| Title | Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer |
| Official title | Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | larotaxel (XRP9881), trastuzumab |
| Enrollment | 6 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Oct 13, 2006 |
| Last update posted | May 5, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: